Neurocrine Biosciences Reports Mixed Q4
Neurological therapeutics specialist Neurocrine Biosciences (NASDAQ:NBIX) reported mixed fourth-quarter earnings on Thursday, Feb. 6. Despite a slight miss on revenue expectations, its adjusted earnings per share (EPS) beat estimates significantly.
Overall, the quarter showcased strong performance, particularly from the flagship prescription medication Ingrezza, underscoring the effectiveness of its strategic initiatives.
| Metric | Q4 2024 | Q4 Estimate | Q4 2023 | Change (YOY) |
|---|---|---|---|---|
| Adjusted EPS | $1.69 | $1.58 | $1.54 | 9.7% |
| Revenue | $627.7 million | $629 million | $515.2 million | 22% |
| Net product sales | $621.2 million | N/A | $507.2 million | 23% |
| Adj. SG&A | $241.6 million | N/A | $194.0 million | 25% |
Source: Neurocrine Biosciences. Note: Analyst consensus estimates for the quarter provided by FactSet. YOY = Year over year. SG&A = Selling, general, and administrative expenses
Understanding Neurocrine Biosciences
Neurocrine Biosciences is a biotechnology company focused on discovering, developing, and marketing treatments for neurological and endocrine-related diseases. The San Diego-based company is best known for Ingrezza, its lead product that accounts for most of its revenue. The drug treats tardive dyskinesia, a disorder characterized by involuntary facial and body movements, and chorea associated with Huntington's disease. The company also has an extensive pipeline addressing multiple conditions such as major depressive disorder and schizophrenia.
In recent years, Neurocrine has concentrated on expanding its research and development (R&D) capabilities and enhancing its product portfolio. This is evident from the significant investment in its pipeline and strategic collaborations with firms like Takeda. Ingrezza's success and ongoing innovation in R&D are fundamental elements of the company's future growth strategy.
Quarterly Highlights
Ingrezza continued to perform well in Q4, with net product sales reaching $615 million, marking a 23% year-over-year increase. This growth was primarily due to high patient demand and improved profit margins. Neurocrine launched a new product, Crenessity, which contributed $2 million in sales, marking its entry into the market following FDA approval in December 2024. The company focused on robust patient outreach and marketing campaigns for these achievements.
On the financial front, the company posted a GAAP net income of $103.1 million, or a diluted EPS of $1.00 compared to $147.7 million and $1.44 in the previous year. The non-GAAP net income was $173.4 million, showing improved margins due to strong sales in its drug portfolio. Neurocrine's R&D expenses increased by 35% to $185.6 million, highlighting its strong focus on innovation. This budget supported advanced trials for drug candidates like Osavampator for major depressive disorder and NBI-1117568 for schizophrenia.
Competitive pressures remain as a major concern for Neurocrine, given the emergence of similar products from companies like Teva Pharmaceuticals (NYSE:TEVA). To address this, the company emphasizes continuous innovation and further distinguishes its offerings. Further, challenges such as scalability in AI implementation must be managed to maintain competitiveness in the neurological therapeutic space.
Notable balance sheet improvements include an increase in cash and equivalents to $1.8 billion from $1.7 billion, and the repurchase of approximately 2 million shares for $240.5 million under a $300 million share repurchase program.
Looking Ahead
For 2025, Neurocrine's management has projected the net product sales of Ingrezza to reach $2.5 billion to $2.6 billion. Its continued dominance in the product lineup underlines expectations for growth, backed by a broadened market presence. The company also anticipates R&D expenses to range between $960 million and $1.01 billion. Supported by strategic partnerships and ongoing clinical trials, Neurocrine aims to leverage its pipeline for sustained growth.
Investors should watch for further innovation efforts, especially in artificial intelligence (AI) applications within drug development, to assess future scalability potentials. Forward guidance suggests continued focus on diversification with upcoming trials and potential new product launches, placing an emphasis on strategic maneuvers to counter competitive pressures.
Where to invest $1,000 right now
When our analyst team has a stock tip, it can pay to listen. After all, Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 177% for the S&P 500.*
They just revealed what they believe are the 10 best stocks for investors to buy right now…
Learn more »
*Stock Advisor returns as of February 3, 2025
JesterAI is a Foolish AI, based on a variety of Large Language Models (LLMs) and proprietary Motley Fool systems. All articles published by JesterAI are reviewed by our editorial team, and The Motley Fool takes ultimate responsibility for the content of this article. JesterAI cannot own stocks and so it has no positions in any stocks mentioned. The Motley Fool recommends Neurocrine Biosciences. The Motley Fool has a disclosure policy.
Recommended Articles
